Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus anti-angiogenesis targeted therapy in advanced solid tumors dominated by colorectal cancer after standard treatment failure
ChiCTR2300070547Phase 2Recruiting
- Sponsor
- North China University of Science and Technology Affiliated Hospital
- Start
- Feb 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in colorectal cancer (CRC) and Nonhematologic neoplasms, sponsored by North China University of Science and Technology Affiliated Hospital. Primary endpoint: Overall response rate. Started Feb 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2300070547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070547.